Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Inventors

Rich, Stuart • Randall, Douglas • Hay, Douglas

Assignees

Tenax Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11969424-B2

Patent

Publication Date

2024-04-30

Expiration Date


Abstract

This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

Core Innovation

The disclosed approach treats Pulmonary Hypertension Heart Failure with preserved Ejection Fraction (PH-HFpEF) by administering levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof to a human subject. The method aims to improve exercise capacity using an objective measure of six (6) minute walk distance.

The treatment is administered intravenously, orally, or subcutaneously. In the described clinical context, weekly 24-hour levosimendan administration is associated with improvements in pulmonary hemodynamics and functional exercise outcomes.

The document links the exercise-capacity improvement to measurable physiologic effects, including reductions in pulmonary capillary wedge pressure (rest/exercise) and right atrial pressure, and a reduction in mean pulmonary arterial pressure. It also reports increases in cardiac output and improvements in six-minute walk distance, together with quality-of-life measures, and includes tolerability and monitoring information.

Subcutaneous delivery is described as providing formulation- and exposure-related advantages, including reduced peak levosimendan and a similar OR-1896 exposure profile. The document also positions PH-HFpEF as lacking effective therapies and discusses prior levosimendan studies as having excluded HFpEF populations.

Claims Coverage

The independent claim covers a method for improving exercise capacity in a human subject with PH-HFpEF by administering levosimendan, its metabolites OR-1896 or OR-1855, or combinations, via multiple routes, with the exercise outcome anchored to six (6) minute walk distance. Inventive features concentrate on the PH-HFpEF target population, the drug/metabolite selection, route flexibility, and the quantitative exercise-capacity improvement threshold.

Improving six (6) minute walk distance in PH-HFpEF

Administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved Ejection Fraction (PH-HFpEF) an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof to improve exercise capacity by an at least 5 meter increase in the six (6) minute walk distance.

Levosimendan/metabolite administration via intravenous, oral, or subcutaneous routes

Administering levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof intravenously, orally, or subcutaneously.

Overall claim coverage is anchored to achieving at least a 5 meter increase in six (6) minute walk distance in PH-HFpEF by administering levosimendan (or OR-1896/OR-1855), with the core independent structure supported by route options and multiple dependent refinements described in the provided family summary.

Stated Advantages

Improves exercise capacity in a human subject with PH-HFpEF as measured by an at least 5 meter increase in six (6) minute walk distance.

Reduces pulmonary capillary wedge pressure (rest/exercise) and right atrial pressure.

Lowers mean pulmonary arterial pressure.

Increases cardiac output.

Improves quality-of-life measures, including patient-reported outcome assessment tool measures.

Provides safety/tolerability described as comparable/low adverse events versus placebo, including an absence of significant arrhythmias in monitoring.

Subcutaneous delivery is described as reducing peak levosimendan while maintaining a similar OR-1896 exposure profile.

Documented Applications

Treatment of PH-HFpEF in a human subject using levosimendan and/or its metabolites OR-1896 and OR-1855, with exercise-capacity improvement assessed by six-minute walk distance.

Use in clinical evaluation context described as weekly 24-hour levosimendan in the HELP Study and an extension, with reported physiologic and functional outcomes.

Use of subcutaneous administration concepts for levosimendan/metabolites delivery, including formulation-related exposure effects described in the document.

Co-therapy context for a human subject with Cpc-PH-HFpEF involving a pulmonary vasodilator drug together with levosimendan and/or its metabolites OR-1896 or OR-1855.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.